Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 343 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observation for safety Clear all

Conditions: Hepatocellular Carcinoma
Interventions: TBI 302; Biological
Lead sponsor: Evolve Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions: High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Clonal Cytopenia of Undetermined Significance, Cytopenia
Interventions: Inqovi; Drug
Lead sponsor: Lachelle D. Weeks, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Parkinson's Disease
Interventions: CVT-301, Observational cohort; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more

Conditions: Carotid Artery Stenosis, Strokes
Interventions: Statin, Atorvastatin, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 7 more

Conditions: Brain Cancer, Brain Stem Glioma
Interventions: Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy; Drug · Radiation
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Diverticulitis
Interventions: Mesalamine, Probiotic, Placebo, Dietary Advice, Antibiotic for Diverticulitis; Drug · Other
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 36
States / cities: Tucson, Arizona • Los Angeles, California • Merced, California + 33 more

Conditions: Stress Urinary Incontinence
Interventions: Macroplastique; Device
Lead sponsor: Uroplasty, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 19
States / cities: Tucson, Arizona • Irvine, California • Orange, California + 15 more

Conditions: Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Interventions: ABM-168; Drug
Lead sponsor: ABM Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: San Francisco, California • Indianapolis, Indiana • New Brunswick, New Jersey + 3 more

Conditions: Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Interventions: observational study, VOY-101; Other · Biological
Lead sponsor: Perceive Biotherapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah

Conditions: Chronic Lymphocytic Leukemia, Richter's Transformation
Interventions: Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib; Drug
Lead sponsor: Christine Ryan; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more

Conditions: Open Angle Glaucoma
Interventions: CycloPen Cyclodialysis System; Device
Lead sponsor: Iantrek, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more

Conditions: Obstructive Sleep Apnea, Sleep Apnea
Interventions: ProSomnus® EVO Sleep and Snore Device; Device
Lead sponsor: ProSomnus Sleep Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Redwood City, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Divarasib, Pembrolizumab, Nivolumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 10
States / cities: Clovis, California • Bay Pines, Florida • Atlanta, Georgia + 6 more

Conditions: Child Obesity
Interventions: Child Safety Control Intervention, Responsive Parenting Intervention; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Not listed
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Hershey, Pennsylvania • State College, Pennsylvania

Conditions: Edematous Fibrosclerotic Panniculopathy
Interventions: Previously Treated with EN3835; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 2 more

Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Interventions: Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Hemophilia a, Hemophilia B
Interventions: SerpinPC; Drug
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more

Conditions: Ventricular Premature Beats, Contractions, or Systoles, Cardiomyopathies
Interventions: Radiofrequency ablation, Amiodarone (Antiarrhythmic drug); Procedure · Drug
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more

Conditions: Stress Urinary Incontinence
Interventions: iltamiocel; Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Harvard, Massachusetts

Conditions: Large-cell Lymphoma
Interventions: Rapcabtagene autoleucel (YTB323); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Multiple Myeloma
Interventions: BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions: Not listed
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 28
States / cities: Tuscaloosa, Alabama • Costa Mesa, California • Lakewood, California + 21 more

Search by objective public record fields.

Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma

TReatment for ImmUne Mediated PathopHysiology

Early Intervention in High Risk CCUS

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Asacol Acute Diverticulitis(DIVA)Study

Study of Macroplastique Safety and Effectiveness in the Treatment of Female Stress Urinary Incontinence

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

Severe OSA Study (SOS)

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) - Long Term Follow-Up

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)

Observational Registry for Iltamiocel Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo